Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community
Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community
Treatment in the home and hospice of long-term care facilities, particularly for
 non-ambulatory patients, could provide significant advantages for patients and for the
 region. The Calgary Health Region has a unique resource in the home parenteral therapy
 program (HPTP). With the assistance of HPTP, patients requiring bisphosphonate treatment for
 the management of tumor-induced hypercalcemia (TIH) or malignant bone pain (MBP) could be
 treated in the community (ie at home). However, the resources required and the costs
 associated with community-based (homes, hospices, long-term care facilities) treatment of TIH
 and MBP need to be identified and evaluated so as to guide future regional decision making.
Treatment in the home and hospice of long-term care facilities, particularly for
 non-ambulatory patients, could provide significant advantages for patients and for the
 region. The Calgary Health Region has a unique resource in the home parenteral therapy
 program (HPTP). With the assistance of HPTP, patients requiring bisphosphonate treatment for
 the management of TIH or MBP could be treated in the community (ie at home). However, the
 resources required and the costs associated with community-based (homes, hospices, long-term
 care facilities) treatment of TIH and MBP need to be identified and evaluated so as to guide
 future regional decision making.
Inclusion Criteria:

 If hypercalcemic:

 -  Serum corrected Ca+++>= 2.5 mmol/L and symptomatic hypercalcemia

 -  Asymptomatic hypercalcemia with corrected Ca+++>= 3.0 mmol/L

 -  Moderate to severe intolerable pain (>=6/10 on numerical rating scale [NRS]) despite
 optimal treatments with a strong opioid such as morphine, hydromorphone, fentanyl,
 oxycodone or methadone

 -  Radiotherapy bone pain related to metastatic bone disease

 Exclusion Criteria:

 -  Not on a regular bisphosphonate regimen